ACC 2023: Late-Breaking Science Video Collection
Published: 06 March 2023
-
Views:
2725
-
Likes:
7
-
Views:
2725
-
Likes:
7
-
Up Next -
5m 38sPart 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI -
8m 1sPart 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study -
5m 41s -
3m 46s -
5m 53s -
3m 44sPart 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients -
5m 20sPart 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF -
3m 7sPart 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure -
-
33m 28sPart 3 | Session 1 ACC.23 Late-breaking Science Wrap Up -
22:04Part 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
-
16m 22s -
5m 34sPart 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos -
Part 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays -
15m 9sPart 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
16:12Part 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen Harriette Van Spall, Steven E Nissen
-
16:24Part 1 | Session 2 The REVIVED-BCIS2 Viability Study with Dr Harriette Van Spall, Dr Divaka Perera & Dr Peter O'Kane Harriette Van Spall, Divaka Perera, Peter O’Kane
-
Part 1 | Session 3 The BETTER-CARE HF Trial with Dr Harriette Van Spall & Dr Amrita Mukhopadhyay Amrita Mukhopadhyay, Harriette Van Spall
-
17m 32sPart 1 | Session 4 The COORDINATE-Diabetes Trial with Dr Harriette Van Spall, Dr Neha J Pagidipati & Dr Christopher B Granger Christopher B Granger, Harriette Van Spall, Neha Pagidipati
-
12m 7sPart 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti Roberto Diletti, Harriette Van Spall
Overview
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principle investigators for discussion on selected late-breaking trials.
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Highlights Reviews
About the episode
ACC.23/WCC — In this succinct late-breaking science interview, Investigator, Dr Marielle Scherrer-Crosbie (Hospital of the University of Pennsylvania, US) discusses the results from the STOP-CA trial (Massachusetts General Hospital). This randomized phase II trial aims to investigate whether atorvastatin, a commonly prescribed statin drug for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin and prevent heart failure (NCT02943590).
The results presented at ACC.23 showed that among study participants with lymphoma being treated with anthracyclines, the prophylactic use of atorvastatin over 12 months was associated with a lower rate of cardiac systolic dysfunction.
Questions:
- What unmet need does the STOP-CA trial aim to address?
- What is the existing evidence supporting the use of statins in this specific patient population?
- What is the trial design, patient population, and outcome measures?
- What are the key findings?
- What are the implications for patient care?
- What further research is needed?
Recoded on-site at ACC.23, New Orleans.
Comments